Again, great presentation.
A couple of observations that are now public.
One, the ptx team is more assertive in presenting and why not with their clinical programs progressing beyond standard expectations.
Two, the PTX100 ( in design) now about to be tested in mutation x arena...., uncharted waters in clinic studies at this entry level..., as holders, exciting and efficacious times ahead.
One last point of interest, at least to me, that of the company is aware and not prematurely trigger happy to early or rather minor material offers toward any of their therapies. That is, well funded, aware of outside interests yet know that the current therapies are company changing potential.
To sum, although the current SP may not reflect our perception of the company's progress and asserts, nor is it perceived by the company itself.
Strong buy, keep accumulating as management are certainly not sitting on their hands in this company.
PTX Price at posting:
9.1¢ Sentiment: Buy Disclosure: Held
